Roy S. Herbst
Yale Cancer Center
CancerInternal medicineSurgeryPathologyOncologyImmunologyLung cancerChemotherapyCarcinomanon-small cell lung cancer (NSCLC)Epidermal growth factor receptorPembrolizumabDocetaxelNon small cellIn patientCancer researchClinical trialMedicineBiologyPharmacology
Publications 693
#3Christian GrohéH-Index: 51
#5Jonathan W. Goldman (UCLA: University of California, Los Angeles)H-Index: 45
Last. Zhijie Wang (Peking Union Medical College)H-Index: 27
view all 22 authors...
#1M.C. Garassino (U of C: University of Chicago)H-Index: 12
#2Delvys Rodriguez-Abreu (ULPGC: University of Las Palmas de Gran Canaria)H-Index: 33
Last. Hande Turna (Istanbul University)H-Index: 14
view all 24 authors...
Background null Pembrolizumab is a standard-of-care first-line treatment for advanced/metastatic NSCLC, either as monotherapy (for patients with PD-L1 tumor proportion score [TPS] ≥1%) or combined with platinum chemotherapy. An improved OS benefit has been demonstrated for both pembrolizumab monotherapy and pembrolizumab plus chemotherapy in patients with higher tumor PD-L1 expression, and for pembrolizumab monotherapy in patients with higher tissue tumor mutation burden (tTMB). Mutations in KRA...
#1Yi-Long Wu (Peking Union Medical College)H-Index: 96
#2Masahiro TsuboiH-Index: 54
Last. Roy S. Herbst (Yale University)H-Index: 113
view all 23 authors...
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. EGFR stands for 'epidermal growth factor receptor'. It is a protein present on the surface of both healthy and cancer cells that can regulate how cells grow and divid...
#1Fred R. Hirsch (University of Colorado Denver)H-Index: 111
#2Mary W. Redman (Fred Hutchinson Cancer Research Center)H-Index: 29
Last. Philip C. Mack (UC Davis: University of California, Davis)H-Index: 50
view all 11 authors...
Abstract null null Background null The phase III S0819 trial investigated addition of cetuximab to first-line chemotherapy (CT) in NSCLC. Subgroup analyses suggested an OS benefit among patients with EGFR copy number gain in squamous cell carcinomas (SCC), (HR = 0.58 [0.39-0.86], P = .0071). A more detailed model based on EGFR FISH, EGFR IHC and KRAS mutation status was evaluated to yield a more precise predictive paradigm of cetuximab-based therapy in advanced NSCLC. null null null Methods null...
Abstract Introduction In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced non‒small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy/safety follow-up for the KEYNOTE-010 study. Methods Patients were randomized to pembrolizumab 2 mg/kg or 10 mg/kg Q3W, or docetaxel 75 mg/m2 Q3W for up to 35 cycles (2 years). Patients who completed pembrolizumab treatment and su...
#1Alex Martinez-MartiH-Index: 14
#2Margarita MajemH-Index: 29
Last. Philip He (AstraZeneca)H-Index: 6
view all 16 authors...
#6Lawrence Schwartz (Columbia University)H-Index: 51
Importance null Nivolumab plus ipilimumab is superior to platinum-based chemotherapy in treatment-naive advanced non–small cell lung cancer (NSCLC). Nivolumab is superior to docetaxel in advanced pretreated NSCLC. null Objective null To determine whether the addition of ipilimumab to nivolumab improves survival in patients with advanced, pretreated, immunotherapy-naive squamous (Sq) NSCLC. null Design, Setting, and Participants null The Lung Cancer Master Protocol (Lung-MAP) S1400I phase 3, open...
#6Lawrence Schwartz (CUMC: Columbia University Medical Center)H-Index: 51
Introduction null S1400F is a non-match substudy of Lung Cancer Master Protocol (Lung-MAP) evaluating the immunotherapy combination of durvalumab and tremelimumab to overcome resistance to anti-programmed death ligand 1 (PD-(L)1) therapy in patients with advanced squamous lung carcinoma (sq non-small-cell lung cancer (NSCLC)). null Methods null Patients with previously treated sqNSCLC with disease progression after anti-PD-(L)1 monotherapy, who did not qualify for any active molecularly targeted...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.